Markets

Why Novavax Stock Is Sinking Today

What happened

Shares of Novavax (NASDAQ: NVAX) were sinking 12.8% lower as of 12:05 p.m. EDT on Monday. The decline came after Reuters reported that Novavax plans to begin delivering COVID-19 vaccine NVX-CoV2373 to the European Union near the end of 2021 but most of its commitment of up to 200 million doses won't be shipped until next year.

So what

There's good news and bad news with Reuters' report. The good news is that Novavax appears to be close to finalizing a major supply deal with the EU. The company reached a preliminary agreement with the 27-member economic and political union in December. However, the deal wasn't finalized at that time because Novavax has experienced difficulties sourcing some raw materials.

European Union flag with yellow stars in a circle on a blue background and a gloved hand holding a syringe with a needle in front of the flag

Image source: Getty Images.

What's the bad news? Many investors were hoping that Novavax would see European sales for its COVID-19 vaccine sooner than late 2021 and 2022. With the biotech stock falling today, it's clear that the bad news is outweighing the good news in investors' minds.

At this point, neither Novavax nor the EU has officially commented on the supply agreement. However, European Commission President Ursula von der Leyen hinted in late April that a final deal with Novavax could be on the way. In the announcement of an imminent larger supply agreement with Pfizer and BioNTech, she stated, "We will certainly add other potential vaccines, for example protein-based vaccines have also quite a potential." Novavax's NVX-CoV2373 is a protein-based vaccine.

Now what

The most important thing Novavax needs to do now is to win Emergency Use Authorization (EUA) for NVX-CoV2373. The company has already initiated regulatory filings in the EU, U.K., Canada, Australia, and New Zealand.

10 stocks we like better than Novavax
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of February 24, 2021

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NVAX

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More